ArticleBMC oral health2026
Association between primary Sjögren's disease and temporomandibular disorder in Taiwan: a 15-year nationwide cohort, with an exploratory analysis of hydroxychloroquine.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe relationship between primary Sjögren’s disease (pSjD) and temporomandibular disorder (TMD) has received little attention in previous studies. Therefore, we investigated this association using data from a large, population-based cohort.
methodsThis retrospective cohort study analyzed data from Taiwan’s Longitudinal Generation Tracking Database for the period 2000–2015. Patients with pSjD (n = 36,195) were compared with matched controls (n = 144,780). Cox regression analysis estimated the risk of TMD, adjusting for comorbidities and medication exposure.
resultspSjD was significantly associated with an increased risk of TMD (adjusted hazard ratio [aHR] = 1.921, 95% confidence interval = 1.39–2.58, p < 0.001). In secondary analyses, differences in observed incidence were noted across HCQ exposure groups. However, these findings should be interpreted cautiously due to potential confounding by indication and database limitations.
conclusionsThis nationwide cohort study demonstrates a significant association between pSjD and subsequent TMD development. Findings related to HCQ exposure require further investigation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.